News and Announcements
OncoSil Medical Granted UK Central Ethics Approval for Global Clinical Study
- Published April 04, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OncoSil Medical Limited (ASX: OSL) a medical device company focused on localised treatments for patients with pancreatic and liver cancer, is pleased to announce that is has been granted UK Central Ethics Approval for its global clinical study programme for pancreatic cancer.
KEY TAKEAWAYS:
- UK Central Ethics Approval has been granted for the global pancreatic clinical study programme;
- This approval initially for Guys and St Thomas’ Hospital London will now facilitate ethics approval for all 5 participating UK study centres;
- This approval will expedite patient recruitment for the UK arm of clinical study;
- In Australia, Westmead Hospital was granted Ethics approval on 28 March.
The Central Ethics Approval granted on 31 March initially covering Guys and St Thomas’ Hospital, London will facilitate ethics approval for all 5 participating centres in the United Kingdom. This in turn will help expedite the patient recruitment process for the UK arm of the clinical study.
The UK centres participating in the global pancreatic clinical study programme are:
Guy’s and St Thomas’ Hospital, London – lead UK study centre
The University of Leicester
The Royal Liverpool
Hammersmith Hospital, London
Addenbrookes Hospital, Cambridge
In Australia, Westmead Hospital, Sydney was granted ethics approval on 28 March and will over the coming weeks finalise preparation to enrol patients into the study programme.
Westmead Hospital is a specialised tertiary referral hospital for the Western Sydney metropolitan area, serving one of the largest growing population areas in the state of New South Wales.
OncoSil Chief Executive Officer, Daniel Kenny commented:
“We are extremely pleased to have secured Ethics Approval for our global pancreatic clinical study programme in pancreatic cancer at Guys and St Thomas’ Hospital in London. The Guys and St Thomas’ NHS Trust is a highly regarded cancer centre internationally and is also the lead UK centre for our clinical study programme. The granting of Central Ethics Approval now paves the way for the provision of ethics approval across the other four (4) UK study centres. The granting of ethics approval for Westmead Hospital means that shortly this hospital will join St Vincent’s in Sydney and Monash Health in Melbourne in recruiting patients for the clinical programme. ”
Company Updates
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Everything is now competing for the same dollar
Key takeaways As recently as 2022, Germany and Japan could borrow for 30 years at close to zero. That world is gone, and AI is now bidding for what is left. Over the past fortnight, I listened to founders, operators and allocators describe where their industries are heading. They covered four very different frontiers. Each […]
Australia has not held 90 days of fuel since 2012. The fix may start at a sewage plant.
A decommissioned council treatment site in Bundaberg is being built into a $188.9 million biorefinery. Its managing director is candid that the largest revenue line is not yet contracted. Australia has not met its international 90-day fuel reserve obligation since 2012. Around 90 per cent of the country’s liquid fuel is imported. Andy Whitmore, Managing […]
Backed By Leading Investment Groups and Family Offices
